First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers.

Trial Profile

First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2011

At a glance

  • Drugs 4SC 203 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 19 Jan 2011 Results presented in a 4SC AG media release
    • 12 Jan 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top